Ariad Pharmaceuticals Inc. was denied a breakthrough designation from FDA for its ALK/EGFR inhibitor AP26113 in non-small cell lung cancer, the company admitted during its second quarter earnings call, though the firm may try again.
The request was denied “because of the relatively short follow-up of many of the ALK-positive patients treated with ‘113 to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?